ArchiveSee matrix →ES
Peptide

BPC-157

Synthetic pentadecapeptide derived from a protective gastric protein; very popular on social media for repair of tendons, ligaments, and intestinal mucosa. Direct human evidence is practically nil.
Category
Supplement
Scientific evidence
Low
Number of findings
2
Sources
Our own summaries · Cited studies
Recommended dose and how to use
No validated human regimen. In the experimental literature: doses of 200-500 µg/day subcutaneously, for 2-4 weeks, near the injury site. NOT approved by the EMA or FDA.

Regulatory status

Not approved

FDA (U.S.): Not approved. When evaluating it for compounding, the FDA noted possible immunogenicity, impurities, and a lack of human safety data (the proposal was withdrawn).

EMA (EU): Not approved.

How to take it

No validated human regimen. In the experimental literature: doses of 200-500 µg/day subcutaneously, for 2-4 weeks, near the injury site. NOT approved by the EMA or FDA.

Safety

Zero published human trials evaluating long-term safety. Purity of gray-market product varies widely. Banned by WADA for athletes.

Effect by goal · level of evidence

Tendon and joint repair

improves Low preclinical (A)
Animal evidence only

In rats with a severed Achilles tendon, BPC-157 accelerated healing and, in the laboratory, stimulated the growth of tendon cells. There are no controlled clinical trials in humans: its efficacy and safety in people have not been demonstrated.

View the study (preclinical) →

Gastric ulcer and intestinal mucosa

improves Low review (A)
Animal evidence only

Review of the studies from the group that discovered it: in animal models it promotes the healing of ulcers and intestinal mucosal lesions. Not confirmed in trials in people.

View the study (review) →

Information, not medical advice. Scientific evidence reflects the quality of the studies.

Loading assistant…